Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma by Rachel Tanos et al.
RESEARCH ARTICLE Open Access
Select Bcl-2 antagonism restores
chemotherapy sensitivity in high-risk
neuroblastoma
Rachel Tanos1, Dipan Karmali1, Srilatha Nalluri1 and Kelly C. Goldsmith1,2*
Abstract
Background: Pediatric patients with high-risk neuroblastoma (HR NB) often fail to respond to upfront intensive
multimodal therapy. Tumor-acquired suppression of apoptosis contributes to therapy resistance. Many HR NB tumors
depend on the anti-apoptotic protein Bcl-2 for survival, through Bcl-2 sequestration and inhibition of the pro-apoptotic
protein, Bim. Bcl-2 dependent xenografts derived from aggressive human NB tumors are cured with a combination of
cyclophosphamide and ABT-737, a Bcl-2/Bcl-XL/Bcl-w small molecule antagonist. The oral analogue to ABT-737,
Navitoclax (ABT-263), clinically causes an immediate drop in peripheral platelet counts as mature platelets depend
on Bcl-xL for survival. This led to the creation of a Bcl-2 selective inhibitor, ABT-199 (Venetoclax). A Phase I trial of
ABT-199 in CLL showed remarkable antitumor activity and stable patient platelet counts. Given Bcl-XL does not
play a role in HR NB survival, we hypothesized that ABT-199 would be equally potent against HR NB.
Methods: Cytotoxicity and apoptosis were measured in human derived NB cell lines exposed to ABT-199 combinations.
Co-Immunoprecipitation evaluated Bim displacement from Bcl-2, following ABT-199. Murine xenografts of NB cell lines
were grown and then exposed to a 14-day course of ABT-199 alone and with cyclophosphamide.
Results: Bcl-2 dependent NB cell lines are exquisitely sensitive to ABT-199 (IC50 1.5–5 nM) in vitro, where Mcl-1
dependent NBs are completely resistant. Treatment with ABT-199 displaces Bim from Bcl-2 in NB to activate
caspase 3, confirming the restoration of mitochondrial apoptosis. Murine xenografts of Mcl-1 and Bcl-2 dependent
NBs were treated with a two-week course of ABT-199, cyclophosphamide, or ABT-199/cyclophosphamide combination.
Mcl-1 dependent tumors did not respond to ABT-199 alone and showed no significant difference in time to tumor
progression between chemotherapy alone or ABT-199/cyclophosphamide combination. In contrast, Bcl-2 dependent
xenografts responded to ABT-199 alone and had sustained complete remission (CR) to the ABT-199/cyclophosphamide
combination, with one recurrent tumor maintaining Bcl-2 dependence and obtaining a second CR after a second
course of therapy.
Conclusion: HR NB patients are often thrombocytopenic at relapse, raising concerns for therapies like ABT-263 despite
its HR NB tumor targeting potential. Our data confirms that Bcl-2 selective inhibitors like ABT-199 are equally potent in
HR NB in vitro and in vivo and given their lack of platelet toxicity, should be translated into the clinic for HR NB.
Keywords: Bcl-2 homology proteins, Bcl-2 antagonist, ABT-199, Apoptosis, Neuroblastoma
* Correspondence: kgoldsm@emory.edu
1Division of Hematology/Oncology, Aflac Cancer and Blood Disorders Center,
Children’s Healthcare of Atlanta, Atlanta, GA 30322, USA
2Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
30322, USA
© 2016 Tanos et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tanos et al. BMC Cancer  (2016) 16:97 
DOI 10.1186/s12885-016-2129-0
Background
Tumor cells depend on the suppression of apoptosis to
survive the multitude of stressors they encounter on a
daily basis, such as genetic mutations, hypoxia, chemo-
therapy and radiation. Chemotherapy induces the intrinsic
pathway of apoptosis that is tightly regulated by mito-
chondrial resident Bcl-2 family proteins whose structure is
comprised of one to four highly conserved Bcl-2 hom-
ology (BH) domains [1]. Within this family Bcl-2 proteins
with multiple BH domains can be either anti-apoptotic
(Bcl-2, Bcl-XL, Bcl-w, Mcl-1, Bfl-1/A1) or pro-apoptotic
(Bax, Bak) and a subset containing only the BH3 domain
are all pro-apoptotic (Bim, Bid, Puma, Bad, Bik, etc.) [2].
The BH3 domain forms an amphipathic alpha helix that
fits snuggly into the hydrophobic groove of multidomain
members, leading to the specific binding of certain BH3
proteins to select multidomain members. Tumor cells
often increase the expression and/or activity of anti-
apoptotic Bcl-2 members to bind to and sequester
stress-activated BH3 proteins to prevent their binding
to Bax and or Bak to inhibit apoptosis. For example, a
cancer dependent on Bcl-2 for survival, such as chronic
lymphocytic leukemia (CLL), has an abundance of Bcl-2
that actively sequesters the BH3 protein, Bim, making the
cancer cell “primed to die” in the event that other cellular
stressors activate additional BH3 proteins to overcome the
Bcl-2 binding capacity within the cell [3].
Knowledge of the unique primed state of cancer cells
led to the development of novel classes of pro-apoptotic
small molecules that disrupt critical Bcl-2 family protein:
protein interactions to reinstate apoptosis (e.g., HA14-1
[4], AT-101 [5], ABT-737 [6], ABT-263 [7]). The most po-
tent candidates designed to antagonize Bcl-2, Bcl-XL and
Bcl-w includes ABT-737 and its clinical homologue,
ABT-263 (Navitoclax, Abbvie) [6, 8]. ABT-737 mimics
the BH3 protein Bad and targets the hydrophobic pocket
of Bcl-2, Bcl-XL and Bcl-w with low nanomolar affinity.
Navitoclax has been tested in clinical trials for adult
cancers like CLL, AML and Small Cell Lung Carcinoma
[9, 10]. Navitoclax treatment in these trials caused an
immediate drop in the patient’s peripheral platelet count,
potentially putting them at increased risk for bleeding.
This dose limiting toxicity of Navitoclax is caused by its
Bcl-XL -targeting properties as mature circulating platelets
depend on Bcl-XL for survival [11, 12]. Recently, a more
selective Bcl-2 antagonist also from Abbvie, ABT-199
(Venetoclax), became clinically available [13]. When tested
in a phase 1 trial for adult CLL, ABT-199 showed remark-
able tumor killing effects, causing overwhelming tumor
lysis due to its potent on target disruption of Bcl-2 and its
binding partners [13]. ABT-199 selectively targets the
hydrophobic pocket of Bcl-2 and not Bcl-XL, safeguarding
against unacceptable platelet effects [14]. Given these
Bcl-2 select antagonists are well tolerated and performing
well in adult cancer trials, they have high potential to
translate to the pediatric setting to treat Bcl-2 dependent
tumors. Here we provide evidence that this holds true in a
highly lethal pediatric solid tumor known to have func-
tional dependence on Bcl-2, neuroblastoma.
Patients with high-risk neuroblastoma (HR NB) initially
respond to treatment yet > 50 % still die of disease due to
the emergence of chemotherapy resistance [15]. We and
others have shown that chemotherapy induced apoptosis
is inhibited in NB due to alterations in Bcl-2 family
protein interactions at the mitochondria [16]. Bcl-2 de-
pendence in NB, like other cancers, is not due to an
overabundance of Bcl-2 in the cell compared to other
anti-apoptotic members, but due to the functional de-
pendence on Bcl-2 to bind to and sequester activated
Bim [17]. Differences in post-translational modifications
of Bim seem to play a part in determining its selectivity to
Bcl-2 over Mcl-1 in HR NB [18]. We have shown that
ABT-737 in combination with cyclophosphamide, induces
a complete durable tumor response in mice bearing large
xenografts of even the most therapy resistant NB cell
lines, including those with MYCN amplification and ALK
mutations [19]. Functional characterization of Bcl-2
dependence patterns by co-immunoprecipitation (co-IP)
confirmed that ABT-737 sensitive NB cell lines depend on
Bcl-2 and not on Bcl-XL to sequester Bim for survival,
making a large subset of NBs prime candidates for select
Bcl-2 antagonism [19].
Thus our work and others supports a role for the
functional identification and targeting of Bcl-2 mediated
resistance mechanisms in HR NB. We have tested re-
lapsed NB cell lines as well as primary human high-risk
NB tumors and validated that similar Bcl-2 dependence
patterns exist in relapsed as well as primary tumors [19].
In order to facilitate a rapid translation of ABT-199 into
clinical trials for patients with high-risk NB, we demon-
strate with these studies that ABT-199 is just as potent




Neuroblastoma cell lines with MYCN amplification
(IMR-5, SMS-SAN and NB-1643) were used (courtesy
of COG Cell Line Repository and Michael D. Hogarty,
MD, Laboratory, CHOP). Neural cells were grown in
RPMI-1640 (Life Technologies) supplemented with
10 % fetal bovine serum, 2 mM L-Glutamine, 100 U/mL
of penicillin. Tissue culture was at 37 °C in a humidi-
fied atmosphere of 5 % CO2. All cell lines were vali-
dated as unique using STR based genotyping and
confirmed using the COG cell line STR genotype data-
base (www.cog.org).
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Cell viability assays
2 × 104 NB cells/well were plated in triplicate in 96-well
plates in phenol red-free media and allowed to adhere
for 24 h. Cells were then treated with ABT-199, doxo-
rubicin, melphalan or vehicle controls. After 48 h, WST-1
reagent (Roche) was added and absorbance at 590 nM
was recorded and normalized to the background. Error
bars represent the average of the three technical triplicates
and are representative of results seen in two separate
biologic experiments.
PARP cleavage
Cells were treated with the indicated ABT-199 doses for
24 h. Cells were lysed with CHAPS buffer (10 mmol/L
HEPES, 150 mmol/L NaCl, 2 % CHAPS [Sigma Aldrich,
MO]) as previously described [19]. Protein from cell lysate
(25 μg per well) was loaded and an anti-PARP antibody
(Cell Signaling, MA; #9542) was used to detect PARP
cleavage.
Caspase 3/7 assay
2 × 104 cells/well were plated in a 96-well plate and treated
with the appropriate dose of ABT-199 or Etoposide
(Sigma Aldrich, MO) for 24 h. Caspase-Glo 3/7 Assay
kit (Promega, WI; G8090) was used to quantify caspase
activity according to the manufacturer’s specifications.
Error bars represent the average of three separate biologic
experiments.
Annexin/PI apoptosis assay
NB cells were treated with 5 nM ABT-199 or 10 μM
etoposide for 24 h. Following the incubation, cells were
harvested, washed twice with PBS and re-suspended in
Binding Buffer (8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO
4•7H20, 0.24 g KH2PO4) at a concentration of 1 × 10
6
cells/mL. Cells were incubated with Annexin V-PE and
7-AAD (BD Biosciences, CA) for 15 min and then analyzed
immediately by flow cytometry using the FACSCanto II
flow cytometer (BD Biosciences, CA). Histograms rep-
resent percentage of cells found to be Annexin V posi-
tive. Error bars represent the average of two separate
experiments.
Co-immunoprecipitation
Cells were lysed with CHAPS buffer with 300 μg of
protein lysate added to antibody-matrix complex as previ-
ously described [18]. Xenograft tumor sample were
harvested and immediately dissociated though a 0.45 μm
sterile filter, lysed, and immunoprecipitated as above.
Antibodies used as previously described [19].
Murine xenograft studies
Xenografts (IMR5 and NB-1643) were established subcuta-
neously in the flank of 4–6 week old nu/nu athymic mice
(Jackson Laboratories, ME) as described [19]. When tumor
volume reached 150 to 200 mm3, mice were treated either
(i) by intraperitoneal (IP) injection of cyclophosphamide
(CPM: 75 mg/kg) or saline solution IP twice weekly for
2 weeks, (ii) by oral gavage of ABT-199 (100 mg/kg/day for
2 weeks) or vehicle solution, (iii) by a combination of CPM
with ABT-199 at monotherapy dosing/duration. ABT-199
was formulated in a mixture of 60 % Phosal 50 PG, 30 %
PEG 400, and 10 % Ethanol. One animal from the com-
bination treatment was retreated with the same therapy
schedule when the recurrent tumor reached 200 mm3.
Tumor volumes were evaluated using calipers and calcula-
tions using the ellipsoid formula (Length × width2 × 0.52).
Animals were sacrificed when tumor volumes exceeded
2000 mm3, according to the Emory Institutional Animal
Care and Use Committee Guidelines. One mouse with
recurrent tumor from the combination treatment was
sacrificed for tumor co-immunoprecipitation studies.
Mice were housed in a temperature- and light-controlled
pathogen-free facility and given access to sterilized food
and water ad libitum. All animal work abided by and was
carried out under a protocol approved by the Emory
Institutional Animal Care and Use Committee.
Statistical evaluation
Survival analysis were conducted according to the method
of Kaplan-Meier and analyzed by a Mantel-Cox test.
GraphPad Prism software was used to determine statistical
significance between treatments and the IC50 in the cell
survival analyses. P-values < 0.05 were considered statisti-
cally significant.
Results
Select Bcl-2 antagonism potently activates apoptosis in
HR NB cell lines in vitro
NB cell lines previously characterized for different Bcl-2
family dependence patterns [19] were challenged with
identical concentrations of either ABT-199 or ABT-737
and assessed for effects on survival. Our past evaluation of
Bim:Bcl-2 family binding patterns showed that SMS-SAN
has a small amount of Bim bound to Bcl-XL, whereas
NB-1643 has Bim bound exclusively to Bcl-2 [19]. There-
fore, testing SMS-SAN with ABT-199 allowed us to evalu-
ate the efficacy of a selective Bcl-2 inhibitor on an NB that
may codepend on Bcl-XL. NB-1643 and SMS-SAN were
very sensitive to single agent ABT-199 with a similar IC50
as seen with ABT-737 (IC50 1.5 nM and 5 nM, respectively;
Fig. 1a, b). Furthermore, ABT-199 was equipotent as ABT-
263 against SMS-SAN, suggesting this NB depends more
on Bcl-2. Previous data supports this finding as we have
previously shown ABT-737 displaces Bim off of Bcl-2 in
SMS-SAN [19]. IMR5, a MYCN amplified HR NB cell line
characterized as Mcl-1 dependent [17], was completely
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resistant to ABT-199 at concentrations as high as 500 nM,
similar to that seen with ABT-737 (Fig. 1c; [19]).
We then evaluated whether cell death induced by ABT-
199 proceeds through the intrinsic pathway of apoptosis.
Treatment of SMS-SAN with ABT-199 activated both cas-
pases 3 and 7 within 24 h (Fig. 2a). Caspase 3 activation
occurs downstream of the mitochondrial outer membrane
permeabilization (MOMP), supporting that Bim was re-
leased from Bcl-2 to bind to Bax and/or Bak, leading to
the release of cytochrome c from the mitochondria and
ultimate activation of the effector caspases in SMS-SAN.
Apoptosis induction is also supported by the presence of
downstream caspase 3 targets such as cleaved PARP in
SMS-SAN (Fig. 2b). While caspase 3 and/or 7 increase
slightly in IMR5 with ABT-199, this Mcl-1 dependent
cell line does not die in response to even higher doses
of ABT-199 (Fig. 1c). Caspases can participate in add-
itional cellular processes not associated with apoptotic
cell death [20]. Therefore, to validate that caspase 3,7
were activated in SMS-SAN in response to apoptosis
induction, we evaluated for late stage apoptosis, phos-
phatidylserine exposure on the cell surface, by measuring
Annexin V by flow cytometry (Fig. 2c). Annexin V did not
increase in IMR5 in response to treatment with ABT-199
at the same dose (5 nM) that slightly activated cas-
pases. In contrast, Annexin V did increase in SMS-SAN
following ABT-199 exposure (Fig. 2c). We validated that
IMR5 can die by apoptosis in response to a cellular stress
by showing robust caspase activation as well as Annexin
V positivity with a 24 h exposure to etoposide (Fig. 2a, c).
These results confirm that Mcl-1 dependent NBs do not
die by programmed cell death in response to select Bcl-2
antagonism.
ABT-199 displaces Bim from Bcl-2 to induce apoptosis in
high-risk NB cell lines in vitro
The chemical structure of ABT-199 was derived from
the backbone of the ABT-263 scaffold and chemically
manipulated to selectively bind to the hydrophobic pocket
of Bcl-2 [21]. ABT-199 competitively binds to Bcl-2 to ei-
ther displace or prevent the sequestration of death activa-
tor BH3 proteins such as Bim [21]. Given our previous
data implicates Bim is the key death effector in HR NB,
we evaluated whether ABT-199 induces apoptosis in NB
by displacing Bim from Bcl-2. Following treatment of NB
cells with ABT-199, anti-apoptotic multidomain proteins,
Bcl-2 and Mcl-1, were immunoprecipitated and assessed
for Bim binding patterns (Fig. 3). In primary tumors and
cell lines, Bim is rarely found bound to Bcl-XL and those
that show Bim binding Bcl-xL also have Bim bound to
Bcl-2 [19]. In the cell lines tested (NB-1643, IMR5),
Bim is not bound to Bcl-XL [19], therefore, we did not
Fig. 1 Bcl-2 dependent NB cell lines are sensitive to ABT-199 in vitro. Bcl-2 dependent cell lines SMS-SAN (a), NB-1643 (b) were exposed to ABT-737 or
ABT-199 at given concentrations for 48 h and then evaluated for survival by WST-1. Mcl-1 dependent (c) IMR5 was completely resistant to
Bcl-2 antagonism. Values statistically significant from 0 nM control are denoted with stars as follows: (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001,
(****) p ≤ 0.0001, as determined by student’s t test
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immunoprecipitate Bcl-XL in this experiment. In Mcl-1
dependent IMR5, Bim at baseline was bound to both
Bcl-2 and Mcl-1. After treatment of IMR5 with ABT-199,
Bim moved off of Bcl-2, but remained bound to Mcl-1
given ABT-199 has no affinity for Mcl-1 (Fig. 3). Despite
the fact that some Bim is bound to Bcl-2 in IMR5 at base-
line, Mcl-1 is the major contributor to apoptosis resistance
in IMR5, given it is completely resistant to ABT-199 in in
vitro death assays (Fig. 1c). In contrast, Bim is exclusively
bound to Bcl-2 in NB-1643 at baseline (Fig. 3) and expos-
ure to ABT-199 leads to displacement of Bim completely
off of Bcl-2.
ABT-199 augments cytotoxic chemotherapy response in
NBs in vitro
In tumors such as HR NB, cell stresses like chemotherapy
and radiation activate specific BH3-only proteins that then
bind to and prime multidomain anti-apoptotic members
Fig. 2 ABT-199 activates the intrinsic mitochondrial apoptosis pathway in Bcl-2 dependent NBs. a Following a 24 h exposure to increasing concentrations
of ABT-199, both SMS-SAN and NB-1643 (Bcl-2 dependent) show activation of caspases 3 and 7. Mcl-1 dependent cell line, IMR5 does undergo apoptosis
in response to the cytotoxic drug, etoposide, but fails to activate caspases 3 and 7 in response to ABT-199. b Western blot evidence for downstream
PARP cleavage following a 48 h ABT-199 treatment of SMS-SAN. c Following 24 h treatment with etoposide or ABT-199, NB cells were analyzed
for Annexin V positivity, an indicator of cell membrane externalization of phosphatidylserine and late stage apoptosis
Fig. 3 ABT-199 displaces Bim off of Bcl-2, but not Mcl-1 to activate apoptosis. NB cell lines were exposed to ABT-199 for 24 h, followed by co-IP
of anti-apoptotic Bcl-2 or Mcl-1 to assess for changes in Bim binding patterns by western blot in response to select Bcl-2 antagonism
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like Bcl-2. Given the majority of high-risk NB tumors at
diagnosis initially respond to cytotoxic chemotherapy then
ultimately progress due to acquired chemotherapy re-
sistance, we assessed whether ABT-199 could restore
cytotoxic chemotherapy sensitivity in HR NB cell lines.
Similar to responses previously seen with ABT-737 and
chemotherapy, ABT-199 enhances doxorubicin-induced
cell death in Bcl-2 dependent NB cell lines in culture,
decreasing the IC50 significantly (Table 1). ABT-199 also
enhances the cell death effects of the alkylating agent,
melphalan, though not to the degree that it does for
doxorubicin in SMS-SAN. These chemotherapy aug-
menting effects by ABT-199 were not seen for the Mcl-1
dependent cell line IMR5, likely due to ABT-199’s select-
ive antagonism for Bcl-2 (Table 1).
NB xenografts reliant on Bcl-2 for survival have a sustained
complete remission to ABT-199 and cyclophosphamide in vivo
Most high risk NB patients see two or more cycles of
doxorubicin in standard of care upfront therapy and the
risk for severe cardiac toxicity increases with cumulative
dosing. For this reason, doxorubicin is rarely used for
heavily pre-treated patients whose tumors have relapsed.
Therefore, while doxorubicin in vitro combination results
with ABT-199 were more impressive than melphalan
combination results, we chose to test ABT-199 with the
alkylator, cyclophosphamide, in vivo given it is the most
commonly used cytotoxic for combining and translating
novel agents forward into the clinic for HR NB. To ad-
equately compare in vivo responses between previously
tested ABT-737 and current ABT-199 treatment of hu-
man derived NB cell lines xenografted into mice, we
employed the same Mcl-1 dependent (IMR5) and Bcl-2
dependent (NB-1643) cell lines used in prior published
assays, using an identical treatment design as previously
described ([19] and Methods). Following establishment of
a palpable tumor in the flank of athymic nu/nu mice
(150–200 mm3), the mice (n = 8–9/arm for IMR5, 9–10/
arm for NB-1643) were segregated to receive vehicle
control (normal saline by intraperitoneal injection (IP)),
ABT-199 (100 mg/kg oral gavage daily × 14 days),
cyclophosphamide (CPM; 75 mg/kg IP twice weekly ×
2 weeks), or a combination of ABT-199 and CPM at
monotherapy dosing. Results demonstrated that Bcl-2
dependent NB-1643 had an immediate tumor response
to both ABT-199 alone and to the combination of
ABT-199 and CPM, with measurable tumor regression
at the end of treatment (Fig. 4b). IMR5 tumors initially
showed some regression to the combination of ABT-
199 + CPM as well as to CPM alone (Fig. 4a), suggesting
that the CPM and not ABT-199 was the effective compo-
nent of the combination. While IMR5 xenografts initially
responded to CPM, the response was short-lived and all
tumors regrew right after completion of therapy, resulting
in no statistical survival difference between mice treated
with ABT-199 and vehicle, nor the CPM verses CPM+
ABT-199 treatment arms (Fig. 4c). In contrast, the Bcl-2
dependent NB-1643 xenografts had significantly pro-
longed survival after a short monotherapy course of
ABT-199 when compared to vehicle control, and under-
went sustained complete remissions in 7/9 xenografts
treated with the CPM+ABT-199 combination, as far out
as 100 days from the brief 14 day treatment. At day 100,
the 7 mice remaining were sacrificed given they remained
with no detectable tumor. This led to a significant im-
provement in survival for NB1643 mice treated in the
ABT-199 + CPM arm compared to all other arms of the
preclinical trial (Fig. 4d). No toxicities were incurred by
the mice who all maintained normal weight and behavior
in all treatment arms of the experiment. Given the pub-
lished clinical and preclinical data showing the lack of
platelet depression by ABT-199 [13, 14, 21], complete
blood counts were not obtained in this trial.
Bcl-2 dependent NB xenografts that recur following a
short course of ABT-199 maintain Bcl-2 dependence
Two out of nine NB-1643 xenografts that initially had
complete tumor disappearance in response to ABT-199/
CPM combination started to regrow by day 18, four days
from completion of therapy. To assess whether the recur-
rence of tumor was due to an acquired mechanism of
Bcl-2 antagonist resistance, such as an adaptation to
Mcl-1 dependence, we retreated one mouse and assessed
the other tumor for changes in Bim binding by co-IP. The
one mouse with recurrent tumor that was subjected to
a second cycle of therapy (14 days of the same CPM +
Table 1 ABT-199 enhances chemotherapy-induced cell death in
Bcl-2 dependent NBs. SMS-SAN (Bcl-2 dependent) and IMR5 (Mcl-1
dependent) NB cells were exposed to different combinations of
ABT-199 + doxorubicin or ABT-199 +melphalan for 48 h then
evaluated by WST-1 for changes in IC50 of the combination
compared to the cytotoxic chemotherapy given alone. Table
numbers represent the average of three biologic experiments




















aABT-199 and cytotoxic given concurrently in vitro × 48 hours.
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ABT-199 regimen once the tumor reached 200 mm3
again) completely regressed again with no detectable
tumor out as far as day 80 (Fig. 5a). Co-IP of the other
recurrent tumor confirmed our in vivo “retreatment”
findings that the tumors did not change their Bcl-2
family dependence pattern in response to treatment
with ABT-199, as the majority of Bim remained bound
to Bcl-2 (Fig. 5b). Noteably, some Bim is now found
bound to Mcl-1 in the recurrent tumor (Fig. 5b), allud-
ing to the potential for evolution of Mcl-1 dependent
Fig. 4 ABT-199 induces complete tumor regression when given in combination with cyclophophosphamide to aggressive murine models of HR NB. NB
cell line xenografts representing Bcl-2 dependent (NB-1643) and Mcl-1 dependent (IMR5) subclasses were established in the flank of nu/nu athymic mice.
Mice with tumors 150–200 mm3 were randomized to receive either intraperitoneal cyclophosphamide (CPM), oral ABT-199 (A), Cyclophosphamide +
ABT-199 (CPM+A), or vehicle control (C), as outlined in Methods. Waterfall plot of individual tumor volume as % volume change from tumor volume
pre-therapy are depicted for IMR5 (a) and NB1643 (b) tumors. Negative values define best-response tumor shrinkage with −100 % representing complete
regression. Kaplan-Meier curves comparing survival of control (black) versus ABT-737 (blue), and CPM (red) versus CPM+ABT-199 (green) in representative
xenografts of IMR5 (c) and NB1643 (d). p-values derived using the log-rank test. For NB-1643, n= 10 mice per arm; for IMR5, n= 9 mice per arm
Fig. 5 Bcl-2 dependent tumors that recur following ABT-199 therapy maintain Bcl-2 dependence patterns in vivo. 2/9 Bcl-2 dependent tumors
treated with ABT-199 + CPM completely regressed but then regrew. a One mouse received a second round of ABT-199 + CPM therapy (14 days)
that led to a second complete regression of the tumor out to 50 days post second treatment. b The other mouse was sacrificed so that the recurrent
tumor could be profiled for Bcl-2 dependence patterns by co-IP. Co-IP showed that the xenograft maintained Bim bound to Bcl-2 despite its
recurrence. These results suggest that the short duration of treatment led to these two tumor’s growing back
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clone in the tumor if ABT-199 treatments are given for
a longer duration of time. But given the recurrent
tumor still obtained a second complete response to a
repeat course of ABT-199/CPM supports that regrowth
of the only two tumors that were not cured by this ef-
fective combination was likely due to the short duration
of treatment and not acquired resistance.
Discussion
We have previously shown that high-risk NB cell lines
derived from human tumors with the poorest prognosis
can be functionally dependent on Bcl-2 for survival
through Bcl-2’s tonic sequestration of Bim [19]. While
the majority of NB cell lines and primary tumors express
Bcl-XL protein, Bcl-XL fails to sequester Bim or other ac-
tivator BH3 proteins to functionally repress programmed
cell death. Given the absence of Bcl-XL dependence, we
hypothesized that select Bcl-2 antagonism would be
equally as potent as ABT-737 in killing NB tumors and
eventually result in less hematologic side effects when
translated in the clinic. These studies confirmed the po-
tency of select Bcl-2 antagonism in HR NB models.
Given ABT-199 disrupts Bim binding to Bcl-2 at low
nanomolar concentrations in vitro, the superiority of the
combination regimen over ABT-199 alone in vivo does
not indicate that ABT-199 is less effective at inhibiting
its target in vivo. Interestingly, the same in vivo experi-
ments we performed with ABT-737 against NB xenografts
also showed that ABT-737 was more potent in combin-
ation with CPM compared to ABT-737 when given alone.
The second remission noted in the recurrent xenograft
retreated with ABT-199/CPM suggests that a longer treat-
ment duration (>14 days) with ABT-199 either alone or in
combination may reveal the true potency of this drug for
the clinic. Further mechanistic studies are warranted to
understand the contribution a cytotoxic like cyclophos-
phamide has in augmenting the impressive tumor regres-
sion seen in the in situ setting.
We cannot discount the potent effects of cytotoxic
chemotherapy in curing the largest portion of patients
with HR NB and other solid tumors over the years, frankly
at a far higher rate than any targeted therapy has thus far.
Thus the results of these combination studies makes an
argument that novel pro-apoptotic agents like ABT-199
should not be used as a substitute for standard cytotoxics
but as an addition to chemotherapy, to permit the lower-
ing of cytotoxic dosing to decrease normal cell toxicity
while enhancing cytotoxic induced tumor death by re-
instating functional apoptotic machinery to the tumor.
Given the platelet effects of Navitoclax are not seen in pa-
tients clinically treated with ABT-199 supports that this
agent has a higher potential to be used in combination
with cytotoxic drugs in patients with multiply recurrent
NB, who have heavily pretreated marrows with mild
thrombocytopenia at baseline.
Like many tumors, Bcl-2 dependence in neuroblastoma
cannot be determined by expression-based methods alone
but by a functional determination of Bim:anti-apoptotic
Bcl-2 protein binding patterns. Functional assays such as
mitochondrial BH3 profiling, co-IP and more recently
dynamic BH3 profiling can be performed on very small
amounts of solid tumor tissue to successfully characterize
Bcl-2 dependence patterns leading to apoptosis resistance
in chemotherapy refractory solid tumors like NB and
others [17, 19, 22]. Further validation of such assays and
honing them to be performed in the clinical setting using
limited numbers of cells from tumor samples will improve
our ability to match patients to the most effective pro-
apoptotic therapies like ABT-199 and will further pave
the way for using small molecule Bcl-2 antagonists in
the clinic for those pediatric NB patients most likely to
respond.
Conclusions
The extreme clinical responses to ABT-199 seen in patients
with CLL and AML as well as ongoing clinical trials of
ABT-199 in patients with CML sets forth a legitimate role
for select Bcl-2 antagonists in the treatment of “liquid”
tumors. Solid tumors are more heterogeneous, often
having different Bcl-2 anti-apoptotic protein dependence
patterns even within the same tumor type. Our work dem-
onstrates on-target potency of ABT-199 at low nanomolar
dosing as monotherapy as well as improved cytotoxic effi-
cacy with durable remissions when given in combination
with ABT-199 in vivo. Thus this preclinical data sets forth
a platform to translate ABT-199 and cyclophosphamide
combination into a clinical trial, using biologic correlates
in the form of a functional assay to determine those HR
NB patients most likely to benefit from this novel pro-
apoptotic regimen.
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